Abstract submission
The Organising Committee welcomes the submission of abstracts Posters and Oral Presentations for DHM Hybrid 2023.
Abstract submission is officially open and will remain open until 15 February 2023 at 23:59 CET.
Please note that abstracts received after this date will not be considered.
Please note that there will NOT be a Late Breaking Abstract submission
General abstract information
Original laboratory research, clinical research and case presentations are equally welcome.
Presentation Formats:
- Oral Presentation (OAS)
- Poster Discussion Sessions (PDS)
- Poster Display (PD)
Oral Presentation (OAS)
The Oral Presentations will be featured during the selected DHM Hybrid 2023 Sessions. The presentation will consist of 12 presentations of 8 minutes each and each followed by 4 minutes for Q&A. As presenter you are required to prepare a MS PowerPoint presentation featuring the main findings of your work.
Poster Discussion Session (PDS)
The Poster Presentations will take place onsite in Verona in the poster area. Your poster will be available during the entire congress allowing all the registered participants to view it during the whole event. Each abstract presenter will have the opportunity to summarise their main findings and have short presentations of their work to the attendees interested during the Poster Discussion Session (PDS).
Poster Display (PD)
The posters that will be not included in the Poster Discussion Session (PDS) will be available for display during the entire congress.
Abstract topics
o Immediate drug hypersensitivity
o Clinical approach of drug allergy
o Basic Science: Pathomechanism of delayed reactions
o Severe Drug Hypersensitivity Reactions
o Management of patients with Clonal Mast cell Disease and drug
allergy (clinical approach)
o New technologies in drug hypersensitivity (basic science)
o Immunology beyond drug allergy
o New approaches in Drug Hypersensitivity
o Role of the MRGPRX2 receptor for immediate non allergic drug
hypersensitivity reactions
o Drug allergy in children (clinical approach)
o From recent knowledge on pathomechanisms to the bedside (basic
science)
Notification of acceptance
Notification of acceptance or rejection of the abstract will be sent to the presenting author of the abstract by 6 March 2023.
Accepted abstracts will be considered for oral or poster presentations.
The presenting author receives all information concerning the abstract and is responsible for informing all other co-authors of the status of the abstract.
All abstract presenters will be asked to reconfirm their attendance after receiving the notification. If you do not reconfirm your abstract presentation, register and pay the registration fee before the given deadline, your abstract will be removed from the programme.
Contact: Please contact the EAACI DHM Hybrid 2023 Abstract Team at abstract@eaaci.org for all enquiries about abstracts and/or if you do not receive a confirmation e-mail after submitting an abstract (please do not resubmit the abstract).
Travel Grants
A limited number of travel grants will be provided to EAACI Junior Members who are the presenting authors of an accepted abstract. During the submission of your abstract, you can indicate if you are applying for a Travel Grant.
In order to receive a travel, grant you must be registered for the DHM Hybrid 2023 (with the hybrid package) and your registration fee must be paid.
Those who are awarded a travel grant will receive travel costs refunded up to EUR 250.00 and will be reimbursed after the event. Please note that a travel grant does not include the registration fee. The winners of a travel grant will be informed shortly after their abstract notification, by mid-March 2023.